Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals' stock price has been influenced by several events in the past six months. These include a Goldman Sachs analyst upgrade, positive Phase 2 data for atumelnant, encouraging early revenue from Palsonify, the FDA approval of Palsonify, a follow-on equity raise of $350.1 million, the initiation of a Phase 2/3 pediatric trial for atumelnant, and a stock sell-off in January 2025 despite positive Phase 2 data for atumelnant in CAH.

The demand for Crinetics Pharmaceuticals' products and services is generally not subject to significant seasonality, as the need for treatments for rare endocrine diseases and endocrine-related tumors remains consistent throughout the year.

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its pipeline includes Paltusotine (Palsonify), an oral agonist approved for acromegaly; Atumelnant (CRN049894), an oral antagonist in development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome; and CRN09682, the first candidate from Crinetics' nonpeptide drug conjugate (NDC) platform. The company also has programs for hyperinsulinism, hyperparathyroidism, thyroid eye disease, Graves' disease, and obesity.

Crinetics Pharmaceuticals is headquartered in San Diego, California, and has a global strategy for product commercialization. European launches are planned, starting with Germany, and Brazil is being considered for expansion into Latin America.

Crinetics Pharmaceuticals maintains a positive brand reputation due to its commitment to addressing rare endocrine diseases and its scientific advancements. The company's mission, focus on scientific rigor and patient advocacy, successful clinical trial results, the FDA approval of Palsonify, and the debut of its novel Nonpeptide Drug Conjugate (NDC) platform have positively impacted its reputation. There have been no specific events reported in the past year that have negatively affected Crinetics Pharmaceuticals' brand reputation, beyond the general stock market fluctuations.

Crinetics Pharmaceuticals, Inc. has substantial institutional ownership. Major institutional shareholders include Fmr Llc, Vanguard Group Inc, Wellington Management Group Llp, BlackRock, Inc., Driehaus Capital Management Llc, Farallon Capital Management Llc, Price T Rowe Associates Inc /md/, EcoR1 Capital, LLC, and Janus Henderson Group Plc.